HBIO · Harvard Bioscience Inc
$6.66
-0.02 (-0.22%)
At close · Aug 14
Market Cap
$30.30M
Shares
4.55M
Harvard Bioscience Inc Earnings Call Transcripts
Every quarterly earnings call for Harvard Bioscience Inc (HBIO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼9.2%
$26.92M
−$3.40M
'22 Q3
22-11-08
▼14%
$28.43M
−$1.67M
'22 Q4
23-03-09
▲4.2%
$29.98M
$622,000
'23 Q1
23-04-25
▼1.5%
$28.76M
−$980,000
'23 Q2
23-08-08
▼5.8%
$25.36M
−$1.24M
'23 Q3
23-11-07
▼1%
$28.15M
−$1.82M
'23 Q4
24-03-07
▼18.2%
$24.51M
−$4.69M
'24 Q1
24-05-07
▼19.7%
$23.10M
−$2.93M
'24 Q2
24-08-08
▼13.4%
$21.97M
−$4.80M
'24 Q3
24-11-07
▼12.8%
$24.56M
$18,000
'24 Q4
25-03-12
▼11.2%
$21.77M
−$50.34M
'25 Q1
25-05-12
▼11.5%
$20.45M
−$2.28M
'25 Q2
25-08-11
▼6.3%
$20.59M
−$1.23M
'25 Q3
25-11-06
▼3.3%
$23.73M
−$2.85M
'25 Q4
26-03-12
▼4.7%
$20.75M
−$3.42M
'26 Q1
26-05-12
LATEST
▲11.1%
$22.73M
−$2.91M
'26 Q2
26-08-11
Earnings call
FY26 · Q2
2026-08-11
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Revenue
$22.73M
▲ 11.1% YoY Diluted EPS
$-0.64
Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Harvard Bioscience Inc Q1 FY2026 Earnings Call
Positive tone
NPI/translational science products (Mesh MEA, BTX, Soho)
Adjusted EBITDA and profitability
Academic and NIH budget environment
Revenue
$20.75M
▼ 4.7% YoY Diluted EPS
$-0.77
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Harvard Bioscience Inc Q4 FY2025 Earnings Call
Positive tone
Q4 2025 Financial Results
2026 Guidance and Outlook
Financial Restructuring and Refinancing
Revenue
$23.73M*
▼ 3.3% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Harvard Bioscience Inc Q3 FY2025 Earnings Call
Positive tone
Gross margin and adjusted EBITDA expansion
NIH funding and government shutdown risk
Order growth and backlog momentum
Revenue
$20.59M
▼ 6.3% YoY Diluted EPS
$-0.30
Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Harvard Bioscience Inc Q2 FY2025 Earnings Call
Balanced tone
Revenue performance and guidance
NIH and academic budget uncertainty
Tariffs and China/APAC
Revenue
$20.45M
▼ 11.5% YoY Diluted EPS
$-0.52
Gross margin
56.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Harvard Bioscience Inc Q1 FY2025 Earnings Call
Cautious tone
New product launches
Revenue softness
Cost actions and margin pressure
Revenue
$21.77M
▼ 11.2% YoY Diluted EPS
$-11.42
Gross margin
56.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Harvard Bioscience Inc Q4 FY2024 Earnings Call
Balanced tone
Quarterly and annual revenue trends
MEA and MeshMEA product growth
Bioproduction and gene-editing opportunities
Revenue
$24.56M*
▼ 12.8% YoY Gross margin
57.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Harvard Bioscience Inc Q3 FY2024 Earnings Call
Balanced tone
Regional revenue performance
CRO and biopharma spending environment
New product commercialization
Revenue
$21.97M
▼ 13.4% YoY Diluted EPS
$-1.10
Gross margin
58.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Harvard Bioscience Inc Q2 FY2024 Earnings Call
Cautious tone
Preclinical / CRO and biopharma capital spending
New product initiatives and growth drivers
China and Asia Pacific demand
Revenue
$23.10M
▼ 19.7% YoY Diluted EPS
$-0.70
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Harvard Bioscience Inc Q1 FY2024 Earnings Call
Cautious tone
New product launches and high-growth opportunities
Base business and telemetry leadership
Revenue softness and regional headwinds
Revenue
$24.51M
▼ 18.2% YoY Diluted EPS
$-1.10
▼ 1200% YoY Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Harvard Bioscience Inc Q4 FY2023 Earnings Call
Positive tone
New product commercialization
Bioproduction and electroporation
China weakness
Revenue
$28.15M*
▼ 1% YoY Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Harvard Bioscience Inc Q3 FY2023 Earnings Call
Revenue
$25.36M
▼ 5.8% YoY Diluted EPS
$-0.30
Gross margin
58.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Harvard Bioscience Inc Q2 FY2023 Earnings Call
Revenue
$28.76M
▼ 1.5% YoY Diluted EPS
$-0.20
▼ 133.3% YoY Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-25
Harvard Bioscience Inc Q1 FY2023 Earnings Call
Revenue
$29.98M
▲ 4.2% YoY Diluted EPS
$0.10
Gross margin
61.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Harvard Bioscience Inc Q4 FY2022 Earnings Call
Revenue
$28.43M*
▼ 14% YoY Gross margin
55.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Harvard Bioscience Inc Q3 FY2022 Earnings Call
Revenue
$26.92M
▼ 9.2% YoY Diluted EPS
$-0.80
Gross margin
45.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Harvard Bioscience Inc Q2 FY2022 Earnings Call
Revenue
$29.21M
▲ 0% YoY Diluted EPS
$0.60
Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Harvard Bioscience Inc Q1 FY2022 Earnings Call
Revenue
$28.78M
▲ 6.6% YoY Diluted EPS
$-1.70
Gross margin
56.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Harvard Bioscience Inc Q4 FY2021 Earnings Call
Revenue
$33.05M*
▲ 6.7% YoY Gross margin
59.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Harvard Bioscience Inc Q3 FY2021 Earnings Call
Revenue
$29.66M
▲ 23.4% YoY Gross margin
55.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Harvard Bioscience Inc Q2 FY2021 Earnings Call
Revenue
$29.20M
▲ 25.3% YoY Diluted EPS
$-0.10
Gross margin
56.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Harvard Bioscience Inc Q1 FY2021 Earnings Call
Revenue
$26.99M
▲ 13.5% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Harvard Bioscience Inc Q4 FY2020 Earnings Call
Revenue
$30.98M*
▲ 0% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Harvard Bioscience Inc Q3 FY2020 Earnings Call
Revenue
$24.04M
▼ 12.3% YoY Gross margin
56.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Harvard Bioscience Inc Q2 FY2020 Earnings Call
Revenue
$23.31M
▼ 21.2% YoY Diluted EPS
$-0.40
Gross margin
59.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Harvard Bioscience Inc Q1 FY2020 Earnings Call
Revenue
$23.77M
▼ 15.7% YoY Diluted EPS
$-1.20
Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Harvard Bioscience Inc Q4 FY2019 Earnings Call
Revenue
$30.97M
▼ 8.5% YoY Diluted EPS
$0.20
▼ 75% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1123494
CUSIP
416906204
13F (30d)
42 filings
35 filers
Visit website
Investor relations